Skip to main content

Paradigm Biopharmaceuticals (ASX:PAR) logo Paradigm Biopharmaceuticals Health Care
Biotech Healthcare

$0.990 0.060 (6.45%)

High

$1.02

Low

$0.93

Trades

390

Turnover

$1,053,513

Volume

1,077,429
30 June 2023 at 4:10pm
Register to track PAR and receive email alerts.

Short Interest

ASIC data, 5 Oct 2026

% Shorted

0.09%
vs 0.09% prior report

Most Shorted Rank

445th
of 710 shorted ASX stocks

Peak Short

4.77%
Mar 2022

Days to Cover

0.3
at 50d avg vol
View full short position history →
Subject
StockBot
PAR Ann: Half Yearly Report and Accounts

StockBot
PAR Ann: Paradigm Receives $3.38m R&D Tax Incentive Refund

StockBot
PAR Ann: Ethics Approval Received for Synovial Fluid Biomarker Study

StockBot
PAR Ann: Paradigm Welcomes Helen Fisher as Non-Executive Director

StockBot
PAR Ann: Consistent pain reduction and improvement in function data

StockBot
PAR Ann: Statement pursuant to Listing Rule 4.7C.3

StockBot
PAR Ann: Quarterly Update and Appendix 4C - quarterly

StockBot
PAR Ann: Response to ASX Query

StockBot
PAR Ann: Change in substantial holding

StockBot
PAR Ann: Change of Director's Interest Notice

StockBot
PAR Ann: Change of Director's Interest Notice

StockBot
PAR Ann: 39th Annual JP Morgan Healthcare Conference Presentation

StockBot
PAR Ann: Paradigm to present at the J.P. Morgan Healthcare Conference

StockBot
PAR Ann: R&D Investor Presentation

StockBot
PAR Ann: PARADIGM RECEIVES POSTIVE FEEDBACK FROM FDA TYPE C MEETING

StockBot
PAR Ann: Cleansing Notice and Appendix 2A

StockBot
PAR Ann: Initial Director's Interest Notice

StockBot
PAR Ann: Paradigm Provides Phase 3 Clinical Trial Update

StockBot
PAR Ann: Paradigm welcomes Amos Meltzer as Non-Executive Director

StockBot
PAR Ann: Paradigm to Host Inaugural R&D Day

StockBot
PAR Ann: Paradigm to Present at Evercore ISI HealthCONx Conference

StockBot
PAR Ann: Cleansing Notice and Appendix 3G

StockBot
PAR Ann: Final Director's Interest Notice

StockBot
PAR Ann: Resignation of Non-Executive Director

StockBot
PAR Ann: Results of Meeting

StockBot
PAR Ann: Paradigm AGM Presentation

StockBot
PAR Ann: FIRST PATIENT DOSED IN MPS-I PHASE 2 CLINICAL TRIAL

StockBot
PAR Ann: Ordinary Shares Cancellation

StockBot
PAR Ann: Paradigm to present at NWR Virtual Conference

StockBot
PAR Ann: Quarterly Update and Appendix 4C - quarterly

Register to track PAR and receive email alerts.

Similar Companies

CSL ...
CSL
Clinuvel Pharmaceuticals
CUV
Immutep
IMM
Imugene
IMU
Mesoblast
MSB
Opthea
OPT
PYC Therapeutics
PYC
Race Oncology
RAC
Telix Pharmaceuticals
TLX